Clinical Trial

SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study evaluated the overall survival (OS) of SHR-A1904 versus investigator-selected treatment in second-line CLDN18.2-positive advanced GC/GEJC patients
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-17; most recent amendment 2026-05-12.
Status change: Not Yet Recruiting → Recruiting 2024-12-11
Trial Details
NCT Number NCT06649292
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment 524 participants
Start Date 2024-11-22
Primary Completion 2027-09-20 (estimated)
Study Completion 2028-03-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-15